Laboratory Corporation of America Holdings LH | NYSE
After Hours
Company Overview:
10 Year Performance Metrics:
LH Dividend Payments, Yield & Share Price charts
Unlock All Reports & Research Dividend Stocks like a BOSS!
LH Dividend Safety: Payout & Dividend to Free Cash Flow Ratios.
Dividend payout ration is Dividend/EPS, and indicates if company can afford to pay dividends from net income that it earned in the quarter.
Since EPS can be played with using different "accounting gymnastics", a better measure of dividends safety is Dividend to Free Cash Flow (FCF) ratio.
FCF is how much cash the company has earned each quarter, after paying all expenses not related to earnings.
Lower Ratio indicates SAFER Dividend! Ratios consistently close to, or over 100% are usually unsustainable and often indicate a dividend cut might be coming soon.
LH Earnings, Revenue, Cash & Debt, Shares Outstaning:
Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:
Ratios, Profit Margins & Return on Capital:
LH Dividends Info:
LH Dividend History: Dates, Payments & Yield list
Below is a schedule of all LH dividend payments, ex-dates, share price on the day of the payment as well as TTM & forward yield
| Ex-Date | Payment Date | Amount | TTM Yield | Forward Yield | Price on Ex-Date |
|---|---|---|---|---|---|
| 11/26/2024 | 12/13/2024 | $0.720 | 1.21% | 1.21% | $238.73 |
| 08/29/2024 | 09/13/2024 | $0.720 | 1.25% | 1.25% | $229.69 |
| 05/28/2024 | 06/12/2024 | $0.720 | 1.47% | 1.47% | $196.19 |
| 05/24/2024 | 06/12/2024 | $0.720 | 1.44% | 1.44% | $199.65 |
| 02/26/2024 | 03/13/2024 | $0.720 | 1.29% | 1.34% | $215.47 |
| 11/07/2023 | 12/12/2023 | $0.720 | 1.29% | 1.39% | $206.97 |
| 08/07/2023 | 09/08/2023 | $0.720 | 1.2% | 1.34% | $214.40 |
| 05/17/2023 | 06/08/2023 | $0.619 | 1.33% | 1.33% | $186.49 |
| 02/22/2023 | 03/13/2023 | $0.619 | 1.19% | 1.19% | $208.24 |
| 11/16/2022 | 12/09/2022 | $0.720 | 1.03% | 1.38% | $209.45 |
| 08/17/2022 | 09/09/2022 | $0.720 | 0.66% | 1.32% | $217.61 |
| 05/18/2022 | 06/09/2022 | $0.720 | 0.35% | 1.38% | $208.29 |
| 03/29/1994 | 04/26/1994 | $0.200 | 2.76% | 2.76% | $28.99 |
| 12/29/1993 | 01/25/1994 | $0.200 | 2.68% | 2.68% | $29.80 |
| 09/29/1993 | 10/26/1993 | $0.200 | 2.4% | 2.4% | $33.29 |
| 06/29/1993 | 07/27/1993 | $0.200 | 2.07% | 2.07% | $38.66 |
| 03/31/1993 | 04/27/1993 | $0.200 | 2.18% | 2.18% | $36.78 |
| 12/29/1992 | 01/26/1993 | $0.200 | 2.05% | 2.11% | $37.85 |
| 09/28/1992 | 10/23/1992 | $0.200 | 1.76% | 1.87% | $42.69 |
| 06/26/1992 | 07/23/1992 | $0.200 | 1.72% | 1.9% | $42.15 |
| 03/31/1992 | 04/27/1992 | $0.175 | 1.32% | 1.32% | $53.16 |
| 01/06/1992 | 01/31/1992 | $0.175 | 1.15% | 1.2% | $58.53 |
| 09/30/1991 | 10/28/1991 | $0.175 | 1.42% | 1.52% | $45.91 |
| 06/27/1991 | 07/24/1991 | $0.175 | 1.15% | 1.69% | $41.34 |
| 04/04/1991 | 04/29/1991 | $0.150 | 0.73% | 1.46% | $41.08 |
| 12/31/1990 | 01/28/1991 | $0.150 | 0.63% | 2.54% | $23.63 |
Get the best Dividend Stock Research Tools:
Projected Future Returns & Dividends for LH
Based on past 10-year performance, here are LH growth metrics:Using LH CAGR metrics, we can estimate, that your initial $10000 investment, over next 10 years ago, should grow with dividends being reinvested (DRIP) as follows:
Share price CAGR of +9.52%
Dividend CAGR of +16.98%
| LH | |
|---|---|
| Current Price | $228.61 |
| Start Shares | 43.74 |
| Start Value | $10,000 |
| After 10 years: | |
| Final Share Count | 51.96 |
| Dividends Payment | $3.46 |
| Annual Dividends | $718 |
| Yield on cost | 7.18% |
| Share Price | $518.44 |
| Total Dividends | $3,107 |
| Final Value | $26,938 |
NOTE: Above numbers are our estimate based on LH's Dividend and Price CAGR over past 10 years.
These numebrs should only be considered as "potential future returns"! These numbers assume DRIP (reinvesting dividends).
We cannot guarantee that your actual returns will meet these estimates.
Company Info
Laboratory Corporation of America Holdings (LH) had its IPO on 1990-03-29, and is trader on NYSE stock exchange.
Laboratory Corporation of America Holdings operates as a global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C and vitamin D, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, and parentage and donor testing; and occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests. It provides online and mobile applications to enable patients to check test results; and online applications for managed care organizations and accountable care organizations. It offers end-to-end drug development, medical device, and companion diagnostic development solutions from early-stage research to clinical development and commercial market access. It serves managed care organizations, pharmaceutical, biotechnology, medical device and diagnostics companies, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, and independent clinical laboratories. Laboratory Corporation of America Holdings has a collaboration agreement with Tigerlily Foundation to increase clinical trial diversity for women of color. The company was incorporated in 1994 and is headquartered in Burlington, North Carolina.
LH website: https://www.labcorp.com
